Accelerate Diagnostics Inc (NASDAQ:AXDX) saw unusually large options trading activity on Tuesday. Traders acquired 2,249 put options on the stock. This represents an increase of 1,506% compared to the average volume of 140 put options.

Several research firms recently weighed in on AXDX. BidaskClub cut shares of Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 26th. Zacks Investment Research upgraded shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. JPMorgan Chase & Co. cut shares of Accelerate Diagnostics from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $25.00 to $16.00 in a research report on Wednesday, November 7th. Finally, Piper Jaffray Companies decreased their price objective on shares of Accelerate Diagnostics to $17.00 and set an “overweight” rating on the stock in a research report on Friday, January 11th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $17.50.

Shares of NASDAQ AXDX opened at $16.56 on Thursday. Accelerate Diagnostics has a one year low of $10.23 and a one year high of $30.35. The company has a current ratio of 35.26, a quick ratio of 33.54 and a debt-to-equity ratio of 1.52. The company has a market cap of $908.37 million, a price-to-earnings ratio of -14.28 and a beta of 2.51.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its quarterly earnings results on Tuesday, November 6th. The medical research company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). Accelerate Diagnostics had a negative net margin of 1,365.75% and a negative return on equity of 81.76%. The business had revenue of $1.36 million for the quarter, compared to analysts’ expectations of $2.89 million. As a group, sell-side analysts predict that Accelerate Diagnostics will post -1.62 EPS for the current fiscal year.

In related news, Director Thomas D. Brown acquired 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 28th. The shares were bought at an average cost of $13.65 per share, for a total transaction of $136,500.00. Following the completion of the transaction, the director now owns 16,381 shares in the company, valued at $223,600.65. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders purchased 21,600 shares of company stock worth $308,301. 49.30% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC grew its position in Accelerate Diagnostics by 97.8% during the second quarter. FMR LLC now owns 486,500 shares of the medical research company’s stock valued at $10,849,000 after acquiring an additional 240,600 shares during the last quarter. BlackRock Inc. grew its position in Accelerate Diagnostics by 4.2% during the second quarter. BlackRock Inc. now owns 1,750,891 shares of the medical research company’s stock valued at $39,046,000 after acquiring an additional 70,447 shares during the last quarter. Baird Financial Group Inc. grew its position in Accelerate Diagnostics by 4.8% during the third quarter. Baird Financial Group Inc. now owns 161,737 shares of the medical research company’s stock valued at $3,549,000 after acquiring an additional 7,378 shares during the last quarter. Credit Suisse AG grew its position in Accelerate Diagnostics by 5.0% during the third quarter. Credit Suisse AG now owns 3,653,892 shares of the medical research company’s stock valued at $83,856,000 after acquiring an additional 173,289 shares during the last quarter. Finally, Trellus Management Company LLC bought a new position in Accelerate Diagnostics during the third quarter valued at approximately $566,000. Institutional investors and hedge funds own 48.52% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Accelerate Diagnostics Target of Unusually Large Options Trading (AXDX)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2019/01/24/accelerate-diagnostics-target-of-unusually-large-options-trading-axdx.html.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

See Also: How does inflation affect different investments?

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.